These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 26929611)

  • 41. Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer.
    Chen Y; Li J; Chen S; Zhang Y; Hu Y; Zhang G; Yan X; Jiao S
    Sci Rep; 2017 Sep; 7(1):10760. PubMed ID: 28883517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer.
    Kato Y; Okuma Y; Watanabe K; Yomota M; Kawai S; Hosomi Y; Okamura T
    Cancer Chemother Pharmacol; 2019 Aug; 84(2):351-358. PubMed ID: 30993397
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessing the clinical outcome of nab-paclitaxel in Chinese patients with advanced non-small-cell lung cancer.
    Zeng J; Yin J; Yuan D; Yang W; Liang W; Wu G; Song Y
    Clin Respir J; 2017 Sep; 11(5):632-639. PubMed ID: 26404101
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative Effectiveness and Resource Usage in Patients Receiving First-line Taxane-based Chemotherapy for Stage IV Non-Small-cell Lung Cancer in a US Community Oncology Setting.
    Weiss J; Force RW; Pugmire BA; Peterson T; Faria C; Margunato-Debay S; Patel MB
    Clin Lung Cancer; 2017 Jul; 18(4):372-380.e1. PubMed ID: 28117221
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
    Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
    J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Weekly regimen of paclitaxel and carboplatin as first-line chemotherapy in elderly patients with stage IIIB-IV non small cell lung cancer (NSCLC): results of a phase II study.
    Rozzi A; Nardoni C; Corona M; Restuccia MR; Falbo T; Lanzetta G
    J Chemother; 2010 Dec; 22(6):419-23. PubMed ID: 21303751
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.
    Yumuk PF; Turhal NS; Gumus M; Hatabay NF; Turken O; Ozkan A; Salepci T; Aliustaoglu M; Ahiskali R
    BMC Cancer; 2005 Jan; 5():10. PubMed ID: 15667664
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as 
Second-line Treatment for Small Cell Lung Cancer].
    Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
    Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
    Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
    Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial.
    Zhang W; Du C; Sun Y; Yang L; Cui C; Jiang Z; Wang C; Wang J; Zhou A
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):655-660. PubMed ID: 30054709
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
    Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non-small cell lung cancer.
    Igawa S; Otani S; Nakahara Y; Ryuge S; Hiyoshi Y; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sato Y; Sasaki J; Masuda N
    Invest New Drugs; 2018 Feb; 36(1):45-52. PubMed ID: 28466376
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer.
    Kotake M; Kuwako T; Imai H; Tomizawa Y; Kaira K; Yoshii A; Ochiai M; Miura Y; Osaki T; Sakurai R; Takei K; Minato K; Saito R
    Chemotherapy; 2020; 65(1-2):21-28. PubMed ID: 32674095
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Efficacy and Safety of Bevacizumab Combined with Chemotherapy as Second-line or Later-line Treatment in Advanced Nonsquamous Non-small Cell Lung Cancer].
    Zheng X; Wang H; Zhang G; Yan X; Ma Z
    Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):513-518. PubMed ID: 30037370
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Feasibility study of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected non-small-cell lung cancer: FAST-nab.
    Saji H; Marushima H; Miyazawa T; Sakai H; Kimura H; Kurimoto N; Nakamura H
    Anticancer Drugs; 2017 Aug; 28(7):795-800. PubMed ID: 28538017
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
    Hirsh V; Okamoto I; Hon JK; Page RD; Orsini J; Sakai H; Zhang H; Renschler MF; Socinski MA
    J Thorac Oncol; 2014 Jan; 9(1):83-90. PubMed ID: 24346096
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center.
    Zhu J; Zhang Y; Wang M; Zhang Z; Yue D; Liu S; Pan Y; Wang C
    Med Sci Monit; 2021 Aug; 27():e930738. PubMed ID: 34376631
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer.
    Gao G; Chu H; Zhao L; Gui T; Xu Q; Shi J
    Lung Cancer; 2012 Jun; 76(3):380-6. PubMed ID: 22226626
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Outcomes and Toxicity of Concurrent Radiotherapy with Carboplatin/Paclitaxel 
Administrated Every Three Weeks in Inoperable Advanced 
Non-small Cell Lung Cancer: 
A Retrospective Study from A Single Center].
    Zhao J; Zhang X; Hu K; Wang H; Xu Y; Si X; Zhong W; Huang X; Zhang L; Wang M
    Zhongguo Fei Ai Za Zhi; 2016 Nov; 19(11):731-737. PubMed ID: 27866515
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes in lung cancer: An experience from routine tertiary care setting.
    Thippeswamy R; Patil S; Prashanth P; Sateesh CT; Vittal T; Shashidhara HP; Haridas KM
    Indian J Cancer; 2017; 54(1):276-279. PubMed ID: 29199705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.